Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: Lessons from clinical and translational studies

American Journal of Psychiatry

Volumn 169, Issue 2, 2012, Pages 134-140

  Occhiogrosso, Mallay ^a   Omran, Setareh Salehi ^a   Altemus, Margaret ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIN 1; FLUOXETINE; MILRINONE; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; VASCULOTROPIN;

ARTIFICIAL VENTILATION; CHILD CARE; CLINICAL FEATURE; CLINICAL STUDY; COLD STRESS; CYANOSIS; DEPRESSION; DIAGNOSTIC PROCEDURE; DIAPHRAGM HERNIA; DISEASE ASSOCIATION; EXTRACORPOREAL OXYGENATION; FETUS HYPOXIA; GENETIC POLYMORPHISM; GENETIC RISK; HEART MURMUR; HUMAN; HYPOGLYCEMIA; INFLAMMATION; LUNG BLOOD VESSEL; LUNG HYPOPLASIA; LUNG INJURY; MATERNAL BEHAVIOR; MECONIUM ASPIRATION; NEWBORN HYPOXIA; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERSISTENT PULMONARY HYPERTENSION; POSTMATURITY; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEPSIS; TACHYPNEA; TRANSLATIONAL RESEARCH;

EID: 84857572728     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11040553     Document Type: Review

References (52)

1. US Food and Drug Administration: Increased Risk of Neonatal Persistent Pulmonary Hypertension. 2006. http://www.fda.gov/Drugs/DrugSafety/default.htm
2. Yonkers K, Wisner K, Stewart D, Oberlander T, Dell D, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association. Gen Hosp Psychiatry 2009; 31:403-413
3. Reefhuis J, Rasmussen S, Friedman J: Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:2188-2190
4. Cohen L, Altshuler L, Harlow B: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507 (Pubitemid 43200344)
5. Kinsella M, Monk C: Impact of maternal stress, depression, and anxiety on fetal neurobehavioral development. Clin Obstet Gynecol 2009; 52:425-440
6. Wisner K, Sit D, Hanusa B, Moses-Kolko E, Bogen D, Hunker D, Perel J, Jones-Ivy S, Bodnar L, Singer L: Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557-566
7. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Ohio W, Ehrenkranz RA, Fanaroff AA: Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variations and outcomes. Pediatrics 2000; 105:14-20 (Pubitemid 30035712)
8. Dakshinamurti S: Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005; 39:492-503
9. Latini G, Vecchio AD, DeFelice C, Verrotti A, Bossone E: Persistent pulmonary hypertension of the newborn: therapeutical approach. Mini Rev Med Chem 2008; 8:1507-1513
10. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG: Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2010; 28:19-24
11. Abman S: New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol 1999; 18(suppl):201-204
12. Li D, Liu L, Odouli R: Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod 2009; 24:146-153
13. Chung TKH, Lau TK, Yip ASK, Chiu HFK, Lee DTS: Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63:830-834 (Pubitemid 32911013)
14. Eriksen V, Neilsen LH, Klokker M, Greisen G: Follow-up of 5- to 11-year-old children treated for persistent pulmonary hypertension of the newborn. Acta Paediatr 2009; 98:304-309
15. Källén B, Olausson P: Maternal use of selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801-806
16. Fornaro E, Li D, Pan J, Belik J: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007; 176:1035-1040 (Pubitemid 350127848)
17. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Haraa K: Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr 2001; 160:217-222 (Pubitemid 32250001)
18. Kourembanas S, McQuillan L, Leung G, Faller D: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92:99-104 (Pubitemid 23208985)
19. Abman S: Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease, in Membrane Receptors, Channels, and Transporters in Pulmonary Circulation. Edited by Yuan JX-J, Ward JPT. New York, Humana Press, 2010, pp 323-335
20. Abman SH, Ivy DD: Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr 2011; 23:298-304
21. Storme L, Rairigh RL, Parker TA, Kinsella JP, Abman SH: In vivo evidence for a myogenic response in the fetal pulmonary circulation. Pediatr Res 1999; 45:425-431 (Pubitemid 29157778)
22. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM, Holmes A, Lesch KP, Wendland JR: How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008; 55:932-960
23. MacLean MR: Pulmonary hypertension and the serotonin hypothesis: where are we now? Int J Clin Practice Suppl 2007; 156:27-31
24. Eddahibi S, Guignabert C, Barlier-Mur AM: Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006; 113:1857-1864 (Pubitemid 43739397)
25. Herve P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-254
26. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168:487-493 (Pubitemid 37046880)
27. Li XQ, Hong Y, Wang Y, Zhang XH, Wang HL: Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2006; 33:1047-1051 (Pubitemid 44581566)
28. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S: Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 2009; 136:694-700
29. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Wildlitz AC, Rosenzweig EB, Barst RJ: Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006; 19:370-374 (Pubitemid 44051959)
30. Pawluski J, Galea L, Brain U, Papsdorf M, Oberlander T: Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009; 124:e662-e670
31. Gyawali S, Subaran R, Weissman M, Hershkowitz D, McKenna M, Talari A, Fyer A, Wickramaratne P, Adams P, Hodge S, Schmidt C, Bannon M, Glatt C: Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. Biol psychiatry 2010; 67:331-338
32. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108:1141-1150 (Pubitemid 32995372)
33. Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD: Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. Am Heart J: 2007; 153:426-432 (Pubitemid 46328768)
34. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM: Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13:65-73 (Pubitemid 350275180)
35. Eddahibi S, Hanoun N, Lanfumey L, Lesch K, Raffestin B, Hamon M, Adnot S: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000; 105:1555-1562 (Pubitemid 30390306)
36. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81-84
37. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalichikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor- II gene. Am J Hum Genet 2000; 67:737-744 (Pubitemid 30659603)
38. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA: Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005; 111:607-613 (Pubitemid 40216488)
39. Hansmann G, Perez VAdJ, Alastalo T-P, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M: An antiproliferative BMP-2/PPARg/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118:1846-1857
40. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J: Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1473-L1479 (Pubitemid 47077364)
41. Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo T-P, Powers JM, Wang L, Lawrie A, Ambartsumian N, Schmidt A-M, Berryman M, Ashley RH, Rabinovitch M: S100A4 and BMP-2 co-dependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4 (CLIC 4). Circ Res 2009; 105:639-647
42. Konduri GG, Kim UO: Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009; 56:579-600
43. Reis M, Källén B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723-1733
44. Chambers CD, Hernandez-Diaz S, VanMarter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-587 (Pubitemid 43209105)
45. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R: Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18:246-252
46. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ: Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84:23-27
47. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG: Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28:19-24
48. Hibbard JU: Respiratory morbidity in late preterm births. JAMA 2010; 304:419-425
49. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA: Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120:e272-e282 (Pubitemid 47219476)
50. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 292:2372-2382
51. Boucher N, Koren G, Beaulac-Baillargeon L: Maternal use of venlafaxine near term: correlations between neonatal effects and plasma concentrations. Ther Drug Monit 2009; 31:404-409
52. Oates M: Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull 2003; 67:219-229